grant
Evaluating unique aspects of quiescent ovarian cancer cell biology for therapeutic targets
Organization MAGEE-WOMEN'S RES INST AND FOUNDATIONLocation Pittsburgh, UNITED STATESPosted 15 Jul 2023Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY202520S Catalytic Proteasome20S Core Proteasome20S Proteasome20S ProteosomeAPF-1ATP-Dependent Proteolysis Factor 1Activin-Binding ProteinAdjuvant TherapyAnimalsBindingBioinformaticsBiologic CharacteristicBiologic FactorBiologicalBiological CharacteristicsBiological FactorsBiologyCancer PatientCell BodyCell CycleCell DeathCell Division CycleCell Growth in NumberCell MultiplicationCell ProliferationCell SurvivalCell ViabilityCellsCellular ProliferationCellular biologyCessation of lifeCharacteristicsChemoresistanceCombined Modality TherapyDataDeathDevicesDiseaseDisease ResistanceDisorderExhibitsExpression SignatureFDA approvedFollistatinGene Expression ProfileGene TranscriptionGenetic TranscriptionGoalsHMG-20High Mobility Protein 20HumanImmune mediated therapyImmunologically Directed TherapyImmunotherapyKnock-outKnockoutLinkMacropainMacroxyproteinaseMalignant CellMalignant Ovarian NeoplasmMalignant Ovarian TumorMalignant Tumor of the OvaryMalignant neoplasm of ovaryMediatingMessenger RNAMicrofluidicsModern ManMolecularMolecular InteractionMulticatalytic ProteinaseMultimodal TherapyMultimodal TreatmentOvary CancerPathway interactionsPatient CarePatient Care DeliveryPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPhenotypeProliferatingProsomeProteasomeProteasome Endopeptidase ComplexProteasome InhibitorProteinsProteosomeRNA ExpressionRNA SeqRNA analysisRNA sequencingRNAseqRecurrent diseaseRefractoryRelapseRelapsed DiseaseResidualResidual CancersResidual stateRoleRouteSeaSystemTestingTherapeuticTranscriptionTumor TissueUbiquitinUpregulationWorkYeastsadjuvant treatmentbiologiccancer cellcancer typecare for patientscare of patientscaring for patientscell biologychemoresistantchemotherapychemotherapy resistancechemotherapy resistantcombination therapycombined modality treatmentcombined treatmentdifferential expressiondifferentially expressedeffective therapyeffective treatmentgene expression patterngene expression signaturegenetic approachgenetic strategyimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimprovedimproved outcomein vivoinhibitorknock-downknockdownmRNAmulti-modal therapymulti-modal treatmentmulticatalytic endopeptidase complexnecrocytosisneutralizing antibodynew approachesnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovelnovel approachesnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel strategiesnovel strategynovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetovarian cancerpathwaypatient oriented outcomespharmacologicpreventpreventingrecruitresistance to diseaseresistance to therapyresistant diseaseresistant to diseaseresistant to therapysenescence and its associated secretory phenotypesenescence associated secretomesenescence associated secretory factorssenescence associated secretory pathwaysenescence associated secretory phenotypesenescence associated secretory programsenescence associated secretory proteinssenescent associated secretomesenescent associated secretory phenotypesenescent cellsmall molecular inhibitorsmall molecule inhibitorsocial rolesynthetic lethal interactionsynthetic lethalitytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic resistancetherapeutic targettherapy resistanttranscriptional differencestranscriptional profiletranscriptional signaturetranscriptome sequencingtranscriptomic sequencingtreatment resistanceµfluidic
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
Most ovarian cancer (OvCa) patients develop fatal chemotherapy-resistant disease. Elucidating mechanisms
of chemoresistance in OvCa may identify therapeutic targets to prevent or treat relapsed OvCa. One
understudied mechanism of chemotherapy resistance in OvCa is quiescence. Quiescent cells are transiently
non-proliferating and thus refractory to…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click